36. When treatments means rewriting genetic code
Impossibile aggiungere al carrello
Puoi avere soltanto 50 titoli nel carrello per il checkout.
Riprova più tardi
Riprova più tardi
Rimozione dalla Lista desideri non riuscita.
Riprova più tardi
Non è stato possibile aggiungere il titolo alla Libreria
Per favore riprova
Non è stato possibile seguire il Podcast
Per favore riprova
Esecuzione del comando Non seguire più non riuscita
36. When treatments means rewriting genetic code
-
Letto da:
-
Di:
A proposito di questo titolo
When you hear the name Novartis ($NVS), you probably think of a sprawling Swiss healthcare conglomerate, one of the largest pharmaceutical companies in the world with a hand in everything from prescription drugs to generics. For years, it has been a defensive staple in portfolios, known for its broad diversification and steady dividend.
But the real story is that Novartis has fundamentally changed. Through major strategic moves, including the recent spinoff of its Sandoz generics division, the company has transformed into a "pure-play" innovative medicines company. The new focus is laser-sharp: developing high-margin, patent-protected blockbuster drugs in cutting-edge therapeutic areas like oncology and cardiology. However, by shedding its more stable businesses, Novartis is now entirely dependent on the high-stakes, high-reward game of drug discovery.
We're putting the pipeline under the microscope to determine if this leaner, more focused Novartis is poised for a new era of growth or if it has simply traded stability for a much riskier gamble on innovation.
Created with love by Emil Lazzaroni
2 new episodes per week, until I can find good companies to hold forever.
This is not in any way, shape or form financial advice. You are the sole responsible for the action you take after listening to any of my content.
Always consult a professional before investing.
Ancora nessuna recensione